Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT06995625
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA) (STEVIA)
An Open-Label, Single-Arm, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Tolerability of SNE-101 in Patients With Acute Ischemic Stroke
Sponsor: S&Ebio Co. Ltd.
Conditions
Acute Ischemic Stroke AIS
Interventions
SNE-101
Updated 2 times since 2025 Last updated: Jul 31, 2025 Started: Aug 1, 2025 Primary completion: Mar 31, 2026 Completion: Mar 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Acute Ischemic Stroke AIS and is currently actively recruiting participants. S&Ebio Co. Ltd. leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
2 versions recorded-
Sep 2025 — Present [monthly]
Not Yet Recruiting PHASE1
-
Jun 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- S&Ebio Co. Ltd.
Data source: S&Ebio Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .